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A Whole-Genome Analysis Framework
for Effective Identification of Pathogenic
Regulatory Variants in Mendelian Disease
Damian Smedley,1,2,15 Max Schubach,3,15 Julius O.B. Jacobsen,4,15 Sebastian Ko¨hler,3
Tomasz Zemojtel,3,5 Malte Spielmann,3,6 Marten Ja¨ger,3,7 Harry Hochheiser,8 Nicole L. Washington,9
Julie A. McMurry,10 Melissa A. Haendel,10 Christopher J. Mungall,9 Suzanna E. Lewis,9 Tudor Groza,11,12
Giorgio Valentini,13 and Peter N. Robinson3,6,7,14,16,*
The interpretation of non-coding variants still constitutes a major challenge in the application of whole-genome sequencing in Mende-
lian disease, especially for single-nucleotide and other small non-coding variants. Here we present Genomiser, an analysis framework
that is able not only to score the relevance of variation in the non-coding genome, but also to associate regulatory variants to specific
Mendelian diseases. Genomiser scores variants through either existing methods such as CADD or a bespoke machine learning method
and combines these with allele frequency, regulatory sequences, chromosomal topological domains, and phenotypic relevance
to discover variants associated to specific Mendelian disorders. Overall, Genomiser is able to identify causal regulatory variants as
the top candidate in 77% of simulated whole genomes, allowing effective detection and discovery of regulatory variants in Mendelian
disease.Introduction
Medical genetics is being transformed by next-generation
sequencing (NGS) technologies that enable the simulta-
neous investigation of all relevant disease genes, all pro-
tein-coding genes, and even the entire genome.1,2
Whole-genome sequencing (WGS) can detect a broader
range of genetic variation than other sequencing ap-
proaches, including not only single-nucleotide variants
(SNVs) and insertion or deletions (indels), but also struc-
tural variants such as copy-number variants (CNVs) and
translocations. Pilot studies have shown that WGS can
reveal disease-causing variants missed by other genetic
tests.3 In addition to interrogating more of the non-coding
genome, WGS also has better coverage, even in exome re-
gions.3 Therefore, WGS is best poised to investigate the
relevance of nucleotide substitutions and other small
non-coding variants (NCVs) inMendelian disease, but sub-
stantial obstacles remain.
We hypothesize that the rarity of reported Mendelian
regulatory mutations is related to a long-standing observa-
tional bias toward coding sequences in human genetic
diagnostic and research projects. Genome-wide association
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 2016 American Society of Human Genetics.associations (p < 105) between diseases or traits and
SNVs, most of which are located in non-coding se-
quences;4 however, in Mendelian disease, mutations in
non-coding regions represent a tiny minority of all those
published to date. In fact, of the more than 100,000
Mendelian-disease-causing variants in ClinVar,5 the vast
majority affect coding sequences or conserved splice sites.
Accordingly, a large number of bioinformatics tools have
been developed to predict the pathogenicity of sequence
variants in these traditional categories.6 The ‘‘regulatory
code’’ that determines whether and how a given genetic
variant affects the function of a regulatory element re-
mains poorly understood for most classes of regulatory
variation. Thus, given our lack of understanding and tool-
ing, it is not surprising that so far very few disease-causing
NCVs less than 25 nucleotides have been identified as
causal in Mendelian disease. To address this, we therefore
sought to develop an effective approach to detect regulato-
ry variants causative of Mendelian disease.
Recently, several machine learning (ML) methods have
been developed to evaluate arbitrary genomic SNVs with
respect to their potential to cause disease or affect genetic
regulation.7–11 None of the methods were designed specif-
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plete framework for the prioritization of NCVs and
discovery of SNVs causative of specific Mendelian diseases.
It has been designed primarily for use in two contexts: clin-
ical diagnosis and novel disease gene identification. Our
approach combines two major components: (1) a machine
learning method for scoring NCVs and (2) an integrative
algorithm for ranking NCVs in whole-genome sequence
data. The ML method scores each position of the non-
coding genome based on predicted pathogenicity in
Mendelian diseases. The integrative algorithm factors in
multiple inputs: (1) phenotypes, (2) variants in coding re-
gions, (3) variants in non-coding regions, and (4) existing
published gene-phenotype associations. We show by
cross-validation studies that the ML method outperforms
previous, more general-purpose, pathogenicity scoring
schemes in the particular task of identifying Mendelian
disease-associated variants. Simulations performed for
more than 10,000 case subjects were able to recover the
correct regulatory variant in first place in 77% of diagnostic
genomes.Material and Methods
Observed Probably Non-deleterious Variant Sites
We identified single-nucleotide sites in the human genome at
which the human genome reference sequence differs from the in-
ferred ancestral primate genome based on the Ensembl Enredo-
Pecan-Ortheus (EPO) whole-genome alignments of six primate
species12,13 (Ensembl Compara release e71). A file containing the
inferred ancestral sequences was downloaded from the 1000
Genomes Project website. We selected all positions of high-
confidence alignments that differed from the human reference
sequence (hg19). Low-confidence calls are defined in the file as
those where the ancestral state is supported by one sequence
only. This file was compared with the human (Homo sapiens)
genome sequence (hg19) via an in-house Java program that cata-
loged the differences found according to location with respect to
genomic annotations.
We excluded nucleotide positions associated with variants pre-
sent in the most recent 1000 Genomes Project14 data at a fre-
quency of higher than 5% (meaning that the derived allele in
the human genome is present at a frequency of less than 95% so
that it is less certain that the allele has been exposed to many
generations of natural selection). The file ALL.wgs.phase3_
shapeit2_mvncall_integrated_v5a.20130502.sites.vcf was down-
loaded from the 1000 Genomes Project FTP site on May 30,
2015, and the AF (allele frequency) field was used as the threshold.
All variants were annotated with Jannovar15 v.0.14 using NCBI
Reference Sequence Database16 (annotation release 105) and
only variants of non-coding variant effect are used as final non-
deleterious variant sites (negative positions). Table S1 shows the
distribution of variants extracted in this way and the variant cate-
gories selected for analysis are marked. This yielded a total of
14,755,199 sites; because deleterious variants are depleted by nat-
ural selection in fixed or nearly fixed derived alleles, we infer that
variation in these sites is unlikely to be associated with Mendelian
disease, and we therefore chose to use this set of genomic sites as
negative examples for training.2 The American Journal of Human Genetics 99, 1–12, September 1, 2Biocuration of Non-coding Mendelian Disease-
Associated Mutations
Comprehensive literature review was performed to identify non-
coding variants that are convincingly associated with Mendelian
disease. We included only those variations and publications
judged to provide plausible evidence of pathogenicity. First, the
phenotypic abnormalities of the individual carrying the variant
were assessed and a variant was included only if the disease asso-
ciation was regarded as plausible on the basis of evidence such
as familial cosegregation or experimental validation, using tech-
niques such as luciferase reporter assays, electrophoretic mobility
assay, or telomerase activity assay. In some cases pathogenicity
was assigned based on curator judgment or computational
predictions; for instance, mutations in RNA genes that affected
RNA secondary structure elements such as stem loops were
included. To identify articles for biocuration, a number of review
articles were consulted on non-coding mutations,17–23 including
50 and 30 untranslated region (UTR) mutations,24–29 enhancer
mutations,30–32 promoter mutations,33,34 and mutations affecting
microRNA (miRNA) genes or miRNA recognition sites in
mRNAs.35–38 Additionally, locus-specific databases were consulted
for selected genes.39–41 We did not include variants that represent
susceptibility loci for common, complex disease (i.e., ‘‘GWAS hits’’
were excluded). Likewise, somatic variants associated with cancer
were not included. A total of 453 unique non-coding Mendelian
disease-associated variants were identified (Table S6). Mutations
were manually mapped to GRCh37, if necessary. Each variant
was cataloged according to its sequence variant type (Table 1).
The disease associated with the variant was mapped to an OMIM
disease identifier, and the affected gene was encoded with an
NCBI Entrez Gene identifier.Genomic Attributes Used for Machine Learning
Every position in the genome was annotated with 26 numeric
features. Conservation scores PhastCons and PhyloP42 for 9
primates, 32 mammals, and 45 vertebrates multi-species align-
ments were derived from UCSC.43 GERPþþ element scores and
the corresponding p values were downloaded from the GERP44
website on June 6, 2015. CpG and G/C content as well as the
observed to expected CpG ratio were downloaded directly
from the UCSC table browser45 on June 6, 2015. The GC content
in the human genome (hg19) in a range of 575 nt for every
position was computed (Ns are not counted). Transcription
and regulation annotations were downloaded from UCSC.43
We used the maximum ENCODE H3K27 acetylation level along
with the maximum ENCODE H3K4 methylation level and the
maximum ENCODE H3K4 trimethylation level. DNase hyper-
sensitive scores were derived from the UCSC ENCODE Regula-
tion DNase Clusters track V3 along with the number of overlap-
ping transcription factor binding sites conserved in the human/
mouse/rat alignment. In addition, permissive and robust en-
hancers were taken from the FANTOM5 project.46 Population-
based features were computed by counting the number of rare
(%0.5% AF) and common (>0.5% AF) 1000 Genomes14 (release
5a of 05/02/2013) variants in a window of 5500 and using the
ratio of rare variants (%0.5%) and common variants (>0.5%)
(zero if common variants are zero). Finally, overlapping Data-
base of Genomic Variants47 (DGV), dbVar,48 and ISCA49 (study
IDs nstd37, nstd45, nstd75) CNVs for every position in the
human genome were counted for each position. All attributes
are listed in Table S2.016
Table 1. Mendelian Regulatory Mutations
Category Example Count
Enhancer triphalangeal thumb, type I (SHH [MIM: 174500]) 42
Promoter hemophilia B (F9 [MIM: 306900]) 142
50 UTR 153
Transcription (core promoter) acute intermittent porphyria (HMBS [MIM: 176000]) 52/153
uORF Marie Unna hereditary hypotrichosis (HR [MIM: 146550]) 37/153
Secondary structure hyperferritemia cataract syndrome (FTL [MIM: 600886]) 31/153
Kozak sequence beta thalassemia (HBB [MIM: 613985]) 2/153
Unclassified thrombocytopenia 2 (ANKRD26 [MIM: 188000]) 31/153
30 UTR 43
Polyadenylation permanent neonatal diabetes (INS [MIM: 606176]) 14/43
miRNA binding autosomal-dominant spastic paraplegia 31 (REEP1 [MIM: 610250]) 5/43
Other autosomal-dominant myopia 21 (ZNF644 [MIM: 614167]) 24/43
Large non-coding RNA gene microcephalic osteodysplastic primordial dwarfism, type 1 (RNU4ATAC [MIM: 210710]) 65
MicroRNA gene autosomal-dominant deafness 50 (MIR96 [MIM: 613074]) 5
Imprinting control region Beckwith-Wiedemann syndrome (H19 [MIM: 130650]) 3
Total 453
Total single-nucleotide variants 406
A total of 453 unique, non-coding, regulatory mutations were identified by manual biocuration (Table S6). The pathomechanism of a subset of the 50 and 30 UTR
mutations was indicated in the original publications and is shown here. 406 of the 453 mutations were single-nucleotide variants that were used for machine
learning. One example of a disease caused by each pathomechanistic category is shown together with the affected gene and the OMIM number of the disease.
Please cite this article in press as: Smedley et al., AWhole-Genome Analysis Framework for Effective Identification of Pathogenic Regulatory
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The regulatory Mendelian mutation (ReMM) framework uses ML
techniques to train a classifier to predict the potential of an arbi-
trary position in the non-coding genome to cause aMendelian dis-
ease if mutated. The hand-curated set of Mendelianmutations was
used as a positive training set, and non-coding nucleotides that
have diverged in humans as compared with the inferred ancestral
primate genome sequence were used as a negative training set.
Our experimental setting is characterized by a high imbalance
between the available positive and negative training data: there
were only 453 regulatory Mendelian mutations, of which 406
were single-nucleotide variants suitable for training, compared
with 14,755,199 negative examples. Thus, approximately 36,000
negative examples are available for every positive one. In such
extremely unbalanced conditions, classical computational and
machine learningmethods tend to perform poorly. This is because
they learn overwhelmingly from negative examples, which leads
to a sensitivity and precision close to zero on new (test) data.50
In order to train the ReMMmodel, we first divided the majority
class (probably non-deleterious variant sites) randomly into n ¼
100 partitions and then we added all the minority instances
(non-coding Mendelian mutations) to every partition. We chose
100 partitions because no substantial performance improvements
were observed when more partitions were utilized (data not
shown). Moreover, in each partition we synthetically oversampled
theminority positive class, using the synthetic minority over-sam-
pling technique51 (SMOTE) with a number of nearest neighbors
k¼ 5.With the SMOTE approachwe generated synthetic instances
two times the cardinality of the positive class. We then randomly
undersampled the majority negative class to obtain a three timesThe Amlarger set of negative examples. The resulting dataset was used to
train a random forest (RF) classifier52 (forest size 10; larger forests
do not significantly improve the performances; data not shown)
that outputs a probability to estimate whether a given position
in non-coding genome can cause a Mendelian disease if mutated.
The overall process of over- and undersampling and the training of
the RF was repeated for all the n partitions. Finally, the probabili-
ties estimated by each RF were averaged and the resulting
‘‘consensus’’ probability of the hyperensemble represents the final
ReMM score. Our method was implemented in Java usingWeka.53
One ReMM score was generated for each position of the non-
coding genome, with 0.0 being the least and 1.0 being the highest
prediction of deleteriousness. In order to predict the pathogenicity
of deletions, themaximumReMM score of any nucleotide affected
by the deletion is used (note that our tests include deletions of up
to 24 nt only). For insertions, the maximum ReMM score of the
two nucleotides that surround the insertion are used.Model Testing and Validation
Model performance was tested with a ‘‘cytogenetic band-aware’’
10-fold cross validation: to ensure that mutations of the same loca-
tion, gene, or disease do not occur in the training and test set, we
partitioned the mutations into the chromosomal bands. Bands
with at least one positive mutation were assigned to one of the
ten folds so that each fold contains around 40 positives. The re-
maining bands were randomly assigned to the different folds
and negative variants were added to the partition of their
associated band. For each round of the cross-validation, the nine
folds corresponding to the training set underwent a subdivisionerican Journal of Human Genetics 99, 1–12, September 1, 2016 3
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The trained ensemble was then tested on the remaining held-out
unchanged fold not used for training. In this way, across the ten
rounds of the cross-validation procedure, we tested all the
genomic positions available in our data (more than 14,000,000
genomic positions). For all other positions in the human genome,
we built a global model using the complete negative and positive
positions and annotated the remaining 2,845,135,389 unambigu-
ous (i.e., not ‘‘N’’) positions of the human reference genome
(release hg19).
The ReMM score was compared to the non-coding variant scores
CADD7 v.1.3, GWAVA8 v.1.0, FATHMM-MKL,54 Eigen,11 andDeep-
SEA.10 CADD and Eigen scores are extracted from the provided
precomputed genome-wide file. For Eigen all variants on allo-
somes were removed, because Eigen is available only on auto-
somes. Position scores of GWAVA, FATHMM-MKL (commit
d4af576240fb872179805fb113e892597248441d), and DeepSEA
were computed using the source code provided by the authors.Regulatory Filtering and Genomiser Application
Genomiser was implemented by extending the existing Exomiser
codebase.55,56 To allow Genomiser to run in a reasonable time
frame (~4–10 min) and with a minimal memory (~4–10 GB), we
had to reimplement Exomiser to be able to stream variants from
a VCF file and run the various filtering and prioritization steps
in a user-configured manner rather than the predefined filtering
followed by prioritization steps of Exomiser. We also introduced
the ability to filter genes by their phenotypic similarity so that
as a first step genes associated with diseases that have little or no
similarity to the observed phenotypes can be removed along
with their associated variants. Note in this step, distal (>20 kb
from a gene) variants that reside in predicted enhancers from
the FANTOM5 consortium46 (downloaded on 8/7/15) or Ensembl
regulatory feature build57 (downloaded Ensembl regulatory fea-
tures dataset from Ensembl Biomart on 8/7/2015) are associated
with the most phenotypically similar gene in the topologically
associated domain (TAD)58 containing the enhancer. TADs are
defined using Hi-C to identify higher-order chromatin interac-
tions in the three-dimension organization of the genomes and
they organize the genome into chromosome neighborhoods
within which most enhancer-promoter contact occurs. We re-
placed the existing behavior of removing all non-coding variants
with a new configurable filter that can remove any combination
of variant types or none at all in the case of Genomiser. Pathoge-
nicity scoring was extended to use the REMM scores for all
non-coding variants. In the case of non-coding insertions, the
maximumof the REMM score for the two bases either side of inser-
tion site is used. For non-coding deletions, the highest REMM
score for the deleted positions is taken. Finally, we introduced a
regulatory feature filter where all variants that lie more than
20 kb from a gene are removed unless they lie in one of the
predicted enhancers. The binaries and data for Genomiser are
available as part of Exomiser and are free for academic use from
Exomiser website. The version used in all results presented here
is 7.2.0. The Genomiser_README file describes how to download,
install, and run the application to perform Genomiser analysis.Performance Evaluation
Benchmarking experiments for Genomiser were performed using
10,419 simulated rare disease genomes based on the 453 regula-4 The American Journal of Human Genetics 99, 1–12, September 1, 2tory Mendelian mutations and 1,092 whole-genomes VCF files
from the 1000 Genomes Project14 (05/02/2013 release). For auto-
somal-dominant diseases, one heterozygous mutation was added,
and for autosomal-recessive diseases, either one homozygous mu-
tation or two heterozygous mutations were added to the 1000 Ge-
nomes VCF file. For these experiments, the phenotypic (HPO) an-
notations for the corresponding disease in OMIMwere taken on 8/
7/2015 from the annotation files of the HPO team. To measure the
ability of Genomiser to detect known disease-gene associations,
we repeated the analysis with incomplete (maximum of three
HPO annotations), noisy (two random HPO terms added), and
imprecise (two of the original HPO annotations replaced by the
more general parent terms in the ontology) annotations.
These simulated genomes were run through the default settings
of Genomiser. In the first step, genes and associated variants are
removed where there is little similarity between observed pheno-
types and direct or inferred knowledge from disease and model or-
ganism databases. Note in this step, distal (>20 kb from a gene)
variants that reside in predicted enhancers from FANTOM5 and
Ensembl are associated with the most phenotypically similar
gene in the topological domain containing the enhancer rather
than simply taking the closest gene. Distal variants that do not
reside in a predicted enhancer are removed, followed by the exclu-
sion of any that are common (>1%minor allele frequency [MAF])
in the 1000 Genomes Project, NHLBI Exome Sequencing Project
(ESP), and Exome Aggregation Consortium (ExAC) datasets.
Finally, the remaining variants are prioritized by a composite score
of the minor allele frequency, phenotypic similarity, and pathoge-
nicity (using the ReMM score for non-coding and the existing
hiPHIVE method for coding and splice sequences). To assess our
performance, we measured how often the seeded regulatory Men-
delian variant was ranked first among the full set of the variants of
the simulated Mendelian disease genomes.Results
In this work, we developed a complete framework for the
prioritization of non-coding variants in Mendelian disease
by combining a bespoke pathogenicity score with pheno-
type-based measures of gene candidacy. We first developed
a pathogenicity score to assess Mendelian non-coding vari-
ation. Next we developed methods to integrate the patho-
genicity score, candidate regulatory regions, and the
phenotypic relevance of the associated genes. Here we
describe the development process and present bench-
marking of the entire framework.
The Regulatory Mendelian Mutation Score
We reasoned that ML techniques for building a scoring
model of non-coding Mendelian variants would perform
better with a highly reliable training set, consisting of
mutations that had been validated by experimentation or
co-segregation studies, or for which other convincing evi-
dence of pathogenicity was available. However, to date
such a catalog of validated non-coding variants associated
with Mendelian disease has not existed. Therefore, we per-
formed detailed and comprehensive biocuration to iden-
tify experimentally or otherwise validated non-coding var-
iants (<25 nucleotides) associated with Mendelian disease016
A B Figure 1. Genomic Attributes of Regula-
tory Mendelian Mutations
(A) Centered mean and scaled genomic
attributes of Mendelian non-coding muta-
tions as compared with the derived non-
deleterious positions. Five highly informa-
tive attributes of different attribute groups
are shown. The information content of sin-
gle attributes was computed with a univari-
ate logistic regression model (Table S3).
(B) Principal-component analysis plot
showing the first two principle compo-
nents, which make up 32% of the total
variability.
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were located in 50 and 30 UTRs, promoters, enhancers, large
RNA genes, microRNA genes, and imprinting control re-
gions (ICR) (Table 1, Table S6).
To assess whether the regulatory Mendelian mutations
differ from non-deleterious variants, we compared the reg-
ulatory mutations based upon a set of genomic character-
istics (attributes) representing typical indicators of variant
functionality such as GC-content, conservation, histone
modifications, DNase I accessibility, and overlap with en-
hancers and transcription factor binding sites. Addition-
ally, Mendelian candidacy measures were incorporated,
such as the ratio of rare to common variation around the
position (Table S2). Information content of attributes asso-
ciated with each variant is computed using an univariate
logistic regression model,59 and results are shown in Table
S3. The negative variant set is derived from positions that
differ from the inferred primate ancestral genome with
an allele frequency > 95% (Table S1). The Mendelian regu-
latory mutations displayed a number of substantial differ-
ences as compared to the neutral variants (Figure 1A). Prin-
cipal-component analysis (PCA) was performed on the two
variant classes with all 26 features. The first two compo-
nents show a certain separation between our Mendelian
regulatorymutations and the negative variants (Figure 1B).
This analysis suggested that the genomic attributes
characterizing the nucleotide positions affected by the
Mendelian regulatory mutations differ sufficiently from
those of non-deleterious variants and could therefore be
used to construct a classifier using machine learning tech-
niques. Our experimental setting is characterized by an
extreme imbalance between the available positive and
negative data (406 Mendelian disease-associated SNVs
and 14,755,199 negative data points). As detailed in the
Material and Methods section, we developed a hyper-
ensemble (ensemble of ensembles) approach in which
multiple RFs52 are used as base learners, together with a
combination of over- and undersampling techniques to
compensate for the unbalanced sizes of positive and nega-
tive training data. In total, an ensemble of 100 RFs are
trained in this way to promote balanced and comprehen-The Amsive coverage of the training data. The probabilities of
the 100 RFs are then averaged to compute the Regulatory
Mendelian Mutation (ReMM) score (Figure 2A).
We tested the performance of the ReMM score using a
10-fold ‘‘cytogenetic band-aware’’ cross-validation scheme.
This scheme was designed to minimize bias due to distinct
variants associated with the same disease gene being used
for both training and testing. Cytogenetic bands contain-
ing at least one disease-associated variant were thereby as-
signed to one of ten folds for cross validation, with each
fold containing a total of approximately 40 disease-associ-
ated variants. The remaining bands covering the rest of the
genome were randomly assigned to one of the folds.
Because our ML involves assessing individual genomic
positions, our training set excluded the 47 indels and dinu-
cleotide block mutations. However, in the subsequent
analysis of phenotype-driven prioritization (see below)
and software implementation, we did include deletions
as well as insertions. We evaluated the area under the
receiver operating characteristics (ROC) curve and the
area under the precision-recall (PR) curve to compare our
ReMM score against five other leading scoring methods:
CADD,7 GWAVA,8 FATHMM,54 DeepSEA,10 and Eigen11
(Figures 2B and 2C). PR and ROC curves show that in the
context of the prioritization of the Mendelian mutations,
the ReMM score substantially outperforms other state-of-
the-art scoring methods. It is worth noting that in the
context of extremely unbalanced data, the area under the
PR curve is more informative than the area under the
ROC,60 but even the small differences between the ROC
curves are in most cases statistically significant according
to the Delong test for the comparison of the areas under
dependent ROC curves (Table S4, Supplemental Note, Fig-
ures S1, S2, and S3).
Phenotype-Driven Prioritization of Non-coding
Variants
We and others have previously shown that phenotypic
information can effectively boost the prioritization of
disease-associated genes.1,61,62 Regulatory mutations can
lead to identical or similar phenotypic abnormalities aserican Journal of Human Genetics 99, 1–12, September 1, 2016 5
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Figure 2. Regulatory Mendelian Mutation-Deleteriousness Score
(A) Summary of the algorithm for deriving the ReMM score.
(B and C) Performance comparison between ReMM and other state-of-the-art genome-wide deleteriousness score.
(B) Receiver operating characteristic curves.
(C) Precision-recall curves.
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therefore developed a framework, Genomiser, that com-
bines phenotypic, regulatory, and genotypic information
for the prioritization of non-coding variants associated
with a specific Mendelian disease. Genomiser integrates
our existing hiPHIVE algorithm55,56,63 to exploit pheno-
typic information from human and model organisms,
with the ReMM score to exploit genotypic information,
and relevant distal regulatory sequences into the prioritiza-
tion process. Genomiser is available as an extension to our
existing, freely downloadable Exomiser19 software suite.
The input consists of either a single-sample variant call
format (VCF) or multi-sample VCF with associated pedi-
gree (PED) file, representing the variations in either an
entire human genome or portions thereof. For example,
instead of whole genomes, one could use clinical exome
data containing at least some part of the regulatory
genome such as UTR or proximal promoter sequences.
Additionally, the software requires at least one Human6 The American Journal of Human Genetics 99, 1–12, September 1, 2Phenotype Ontology64 (HPO) term that describes the clin-
ical abnormalities of the individual being investigated.
As shown in Figure 3, Genomiser first of all identifies and
scores the genes that have the most similar phenotypes to
the phenotypic profile under investigation represented us-
ing the HPO terms. This scoring makes use of the hiPHIVE
algorithm to calculate phenotypic similarity based on
either existing phenotypic knowledge from human disease
(OMIM, Orphanet), mouse (MGI, IMPC), and zebrafish
(ZFIN) sources or using guilt-by-association based on prox-
imity in the STRING-DB protein-protein association
network to assign similarity where no phenotypes exist
for a gene. Variants associated with the most phenotypi-
cally similar genes are then retained if they either (1) lie
within a gene including all promoter, UTR, and intronic re-
gions, (2) are within 25 kb up- or down-stream of a gene, or
(3) within predicted regulatory features from FANTOM546
or the Ensembl regulatory build.57 Candidate variants are
assigned to the most phenotypically similar gene within016
Figure 3. The Genomiser Analysis
Framework
Genomiser takes as input a whole-genome
variant call format (VCF) file, a list of
human phenotype ontology (HPO) terms
representing the clinical signs and symp-
toms observed in the individual being
investigated by WGS, and optional user
parameters that control the filtering and
prioritization steps. See text for details of
the prioritization procedure.
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simply taking the closest gene. We have previously shown
that an assessment of regulatory boundaries formed by
topological domains can improve the identification of
candidate pathogenic copy-number variants.65
After this, any common variants (>1% MAF by default)
are removed and, optionally, the known/suspected inher-
itance model used to remove any variants that don’t fit
the expected pattern. The remaining coding or regulatory
variants are then scored according to the allele frequency
and predicted deleteriousness (using the ReMM score for
non-coding and the existing hiPHIVE method for coding
and splice sequences). A composite score based on the
phenotypic similarity of the gene to the observed pheno-
typic profile and the best scoring variant in that gene (or
mean of the best two under a compound heterozygous
model) is then used to rank the genes and their associated
variants.
Genomiser was evaluated by analyzing its capability to
recover a known regulatory Mendelian mutation among
the about 4 million variants included in simulated disease
genomes. To do so, we randomly added one of the regula-
tory Mendelian mutations to a randomly chosen, unaf-
fected whole-genome sequence from the 1000 Genomes
Project14 and ran the resulting genome file through Ge-
nomiser using the default parameters and known inheri-
tance model. We checked whether Genomiser was able to
prioritize the spiked-in regulatory variant as the top candi-
date. We repeated this prioritization experiment on 10,419
simulated disease genomes. We tested Genomiser in three
different experimental conditions, with either (1) no
phenotype information, (2) the full phenotypic profile of
the disease associated with the regulatory variant taken
from our public dataset of HPO disease annotations, orThe American Journal of Huma(3) a more realistic clinical phenotype
profile. For the latter more realistic
clinical scenario, we (1) simulated
incomplete phenotyping by randomly
limiting the profile to three HPO
terms, (2) simulated imprecise pheno-
typing by changing two of these terms
to less specific parental term, and (3)
simulated atypical/confounding pre-
sentation by adding a further two
random HPO terms from the wholeof HPO.1 The recently published Phen-Gen tool61 also
has the capacity to process HPO-encoded phenotypic in-
formation and whole-genome data, so we additionally
compared our performance against this using the same
genomic and phenotypic profiles and identical allele fre-
quency and inheritance model filtering.
Genomiser was able to prioritize the causative, regulato-
ry variant as the top-scoring candidate in 77% of the ge-
nomes when using the full phenotypic profile (Figure 4).
There is a slight reduction in performance to 68%when us-
ing the restricted phenotypic profile that is more likely to
represent the type of phenotype annotations collected in
realistic clinical settings. In both scenarios, our results
represent a substantial improvement over Phen-Gen,
which achieved performances of 19% and 14% using the
full or restricted phenotypes, respectively. Performance
did vary by variant category; the 50 UTR, RNA gene, and
microRNA gene mutations were the easiest to prioritize
and the 30 UTR mutations were particularly difficult.
When phenotype data were not used by Genomiser, the
performance dropped substantially to 23%. Genomiser of-
fers a flexible framework where other non-coding deleteri-
ousness prediction methods such as CADD can be used
instead of using our ReMM score. With CADD, the perfor-
mance was 71% and 61% when using the full or restricted
phenotypic profiles, respectively, and without phenotype
data the causative variant was not seen as the top scoring
hit in any samples.
We note that the ReMM scores used in the Genomiser
experiment were computed by 10-fold cross validation:
the scores for the mutations included in each fold were ob-
tained through amodel trained onmutations not included
in that fold, but only on those of the remaining nine. In
other words, the ReMM score used in Genomiser for an Genetics 99, 1–12, September 1, 2016 7
Figure 4. Performance Evaluation of Genomiser
The curated Mendelian regulatory mutations were added one at a
time to unaffected genomes from the 1000 Genomes Project to
generate 10,419 simulated disease genomes (see Material and
Methods). As an additional test, the same simulations were per-
formed using the CADD score instead of the ReMM score. The ge-
nomes were also run under the same frequency, inheritance, and
phenotype conditions through Phen-Gen. Bars show percentage
of genomes in which the true variant was prioritized as the top
hit when assessing all the genomes or the subcategories involving
promoter, UTR, enhancer, RNA gene, microRNA gene (miRNA),
and imprinting control region (ICR) variants.
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this variant.
Finally, although our focus in this manuscript is on
methods to prioritize non-coding Mendelian mutations,
we note that the Genomiser software application also
makes use of our previously published methods for coding
variants.56,66 To assess the performance of Genomiser on
22 published cases of compound heterozygosity in which
one causal mutation is regulatory and the other is coding
or splice site (Table S5), we spiked both mutations into a
genome VCF file and ran our analysis as above. The causa-
tive gene was ranked top in 18 (84%) of samples, demon-
strating the ability of Genomiser to integrate information
about coding and non-coding variants into the prioritiza-
tion process.Discussion
In this work we have presented a complete framework, Ge-
nomiser, for the prioritization of non-coding variants in
Mendelian disease that offers a quick and effective means
to identify such variants from whole-genome sequences.
The final framework combines ReMMwith other measures
of variant candidacy, predicted regulatory regions, and a
measure of a regulated gene’s candidacy based on similar-
ity of the phenotypic profile observed in an individual un-
der investigation by WGS to existing knowledge, making
use of the integrated cross-species genotype-phenotype
knowledge base developed by the Monarch Initiative.678 The American Journal of Human Genetics 99, 1–12, September 1, 2In 77% of samples, Genomiser is able to identify the caus-
ative regulatory Mendelian mutation as the top candidate
out of the 4 million plus variants in a whole genome. This
approach has the potential to substantially accelerate the
detection of pathogenic, non-coding Mendelian variants
by NGS and to explore the role of this currently under-
studied category of mutations. Although our focus here is
on regulatory variants, Genomiser can still identify causa-
tive coding variants with high accuracy as in the original
Exomiser application.
In order to computationally predict the consequences of
NCVs in the human genome, two types of training data are
required: disease associated (positive) and disease unassoci-
ated (negative). Previous methods have been designed to
detect functional NCVs in general rather than solely those
NCVs that cause Mendelian disease;7–9,68 the latter set is
difficult to find due to the fact that available databases
contain errors69 and conflateMendelian and GWAS-associ-
ated variants. Therefore, for this work, we performed
extensive and detailed literature curation to identify muta-
tions that are associated with Mendelian disease and
whose pathogenicity was judged to be plausible based on
cosegregation, experimental evidence, or similar consider-
ations. Our analysis of this collection of such mutations
showed that they do in fact differ substantially from back-
ground positions in the genome (Figure 1).
This collection allowed us to train a ML classifier using
only Mendelian disease-associated mutations. The meth-
odologies used by CADD, FATHMM-MKL, GWAVA, Deep-
SEA, and EIGEN were designed for substantially larger pos-
itive sets and hence we developed our own ML strategy to
overcome the challenges posed by our unique use case and
make no claim as to the superiority of our method across
all scenarios. However, for the prioritization of Mendelian
mutations in whole-genome sequencing data, the ReMM
score performed much better, as shown in Figure 2 and
in the detailed results provided in the Supplemental Note
and Figures S1–S3. The synergy of different factors explains
the success of ReMM in scoring regulatory Mendelian mu-
tations. At first, ReMM has been designed to deal with
highly imbalanced data (we have a ratio of about
1:36,000 between positive and negative examples) and is
a supervised machine learning algorithm that is designed
to be used when reliable training data is available, such
as our manually curated dataset of non-coding Mendelian
mutations. Second, the oversampling of synthetic positive
examples with SMOTE and the undersampling of negative
examples are key factors to balance training set data and to
avoid biased predictions toward the majority class (nega-
tive variants).50 Third, the adoption of a hyperensemble
strategy allows reliable base learners to be used (each base
learner is a random forest) and also allowed most of the
available search space to be covered, while maintaining a
good balancing between positive and negative examples.
Finally, taking the average of the scores computed by the
hyperensemble of RFs can reduce the variance component
of the error.52016
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able within a start-to-finish application for phenome-
driven WGS analysis such as the Genomiser. The modular
software architecture of Genomiser allows different scoring
methods to prioritize pathogenic variants to be used. By us-
ing CADD instead of ReMM on the same test data, we were
able to rank 71% percent of the pathogenic variants in first
place (versus 77% of top-ranked variants when ReMM is
used; Figure 4). Future work will be needed to determine
whether the ReMM score, or future versions of the ReMM
score or one of the competing scores, will be useful for
the full spectrum of non-coding Mendelian variation,
which could conceivably differ in many ways from the
small set of currently known noncoding Mendelian
variants.
Whichever scoring methodology is used, variant anal-
ysis alone is unlikely to be useful to identify Mendelian dis-
ease-associated variants in WGS data, which typically
contain more than 4 million variants, approximately
40,000 of which are locating in protein coding sequences.
We benchmarked the recall of our regulatory Mendelian
mutations when Genomiser was not used and just the
variant scores alone were used to prioritize the 10,419
simulated whole genomes used in our main experiment.
Using only simple filtering to remove any common vari-
ants with a MAF greater than 1%, prioritization by CADD
or ReMM scores alone was not able to identify the causa-
tive variant as the top hit in any of the samples. Even look-
ing at the top 10 or 100 variants, the causative variant was
seen in only 0.2% and 4% of samples by CADD, and 7%
and 18% by ReMM. This is not surprising because neither
CADD nor ReMM use phenotypic information; rather,
they are designed to assess the potential deleteriousness/
pathogenicity of genetic variants irrespective of a specific
Mendelian disease. Here, we use our phenotype-driven
approach for prioritizing disease genes that we have
developed for and previously applied for CNVs, clinical
exome analysis, and whole-exome analysis.1,66,70 We
then examine regulatory sequences assigned to the genes
that have been prioritized in this way and rank the associ-
ated regulatory variants based on a combination of their
ReMM score, allele frequency, and the similarity of the
observed phenotypic features and existing knowledge of
the gene (Figure 3). We show that our performance is
approximately four times as good as the only previous al-
gorithm able to prioritize WGS data for Mendelian disease
(Phen-Gen61), being able to detect the causative, non-cod-
ing variant as the top candidate in 68%–77% of cases de-
pending on whether a full or more realistic, restricted
phenotypic profile is used (Figure 4). In contrast, Phen-
Gen was able to identify the causative variant as the top
hit in only 14%–19% of samples, depending on whether
the full or restricted phenotypic profile was used. Even
looking at the top 100 variants returned by Phen-Gen,
the causative one was identified in only 31%–34% of sam-
ples. Phen-Gen uses its own model for predicted non-cod-
ing pathogenicity and is trained on positive sets of HGMDThe Amregulatory variants and GWAS hits and a neutral set of
common (>30% allele frequency) variants using evolu-
tionary conservation, function signals from ENCODE,
and proximity to coding regions as properties. The issues
discussed above with these positive sets not fully represent-
ing true disease-causing variants probably accounts for
some of the reduced performance. Given the effort
required in pursuing candidate variants to establish causal-
ity, especially for regulatory variants, computational prior-
itization routines need to regularly place the true causal
variant near the top of the list to be effective. We would
therefore argue that Genomiser offers an effective solution
for identifying causative, non-coding Mendelian variants.
The inclusion of phenotype data is critical for the effec-
tive prioritization of the regulatory variants, with perfor-
mance dropping from 68%–77% to 23% when Genomiser
is run without any input HPO IDs with a consequent
removal of filtering and prioritization by phenotypic simi-
larity score but retention of frequency and regulatory
feature filtering and prioritization by ReMM score and
allele rarity. Although collecting a full and detailed pheno-
typic profile of the individual being investigated by WGS
will certainly improve the chance of prioritizing the cor-
rect causative variant,71 the semantic algorithms underly-
ing Genomiser are robust in that they allow for partial
and non-exact matching between the observed pheno-
types and previous disease and model organism pheno-
typic features associated with the gene. Genomiser offers
the prospect of discovering novel disease-gene association
through the inclusion of model organism data that
extends the phenotypic coverage across the human
proteome, along with the guilt-by-association approach
covering any remaining genes without phenotype data.
Throughout our analysis, coding and non-coding variants
were simultaneously assessed and Genomiser can effec-
tively identify both, as shown by the 84% performance
for identifying compound heterozygous variants involving
a coding and non-coding variant in the disease-associated
gene. Genomiser can be freely downloaded as part of the
Exomiser suite55,66 and will process a whole genome in
around 10 min on a standard desktop computer.
WhereGenomiser failed toprioritizeoneof the regulatory
Mendelian mutations as the top candidate, this was for a
number of reasons. 8%of theMendelian regulatory variants
were lost during the filtering steps, with half lost because
they are distal to a gene but do not yet fall into a predicted
enhancer. In the remaining 16% of cases, the causative
variant is detected but not as the top scoring candidate
due to allele frequencies approaching 1% and/or a low
ReMM score. Finally we note that although Genomiser per-
forms well in the analysis of genomes simulated to contain
non-coding Mendelian mutations, it is currently unclear
how common non-coding Mendelian mutations are and
thus how much of a performance boost can be expected
by approaches such as the one presented here.
Initiatives such as the UK 100,000 Genomes project,
the Precision Medicine Initiative, and many others areerican Journal of Human Genetics 99, 1–12, September 1, 2016 9
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individuals with rare and common disease. However, to
date, a tiny minority of published mutations in Mende-
lian disease have been found in non-coding sequences.
A major but currently unanswerable question is whether
this class of mutations (which comprise at least ten major
pathomechanistic categories; Table 1) are more common
than currently appreciated but simply have not been de-
tected because of the historical focus on protein-coding
exons and the fact that they were rarely sought in the
Sanger sequencing era, and indeed still within most bio-
informatics analysis of NGS data. Non-coding sequences,
such as enhancer elements, have been poorly investi-
gated30 and the challenge of understanding how to
interpret non-coding variants in diagnostic settings or
in projects dedicated to the characterization of novel dis-
ease-associated genes is only beginning to be tackled. The
answer to this question is pressing, because only about
25%–40% of individuals with suspected Mendelian dis-
ease who are investigated in large-scale whole-exome
screening programs actually receive a diagnosis.72–75
Although non-coding mutations not detected by whole-
exome analysis are unlikely to be the only cause for the
lack of a diagnosis in these individuals, WGS puts us
for the first time in the position to test this hypothesis.
In this work, we have presented effective algorithmic ap-
proaches designed especially to address this question,
and we provide an application called the Genomiser
that can be used on mid-range consumer hardware to
analyze VCF files derived from WGS. We have focused
in this report on small (<25 nt) non-coding mutations
for many classes of mutation. A similar approach could
be applied to the analysis of deep intronic splicing muta-
tion and to ‘‘silent’’ changes in coding sequences that
lead to misregulation. It is also likely that as more data
on non-coding Mendelian mutations becomes available,
it will be possible to improve the performance of ML ap-
proaches further and to develop bespoke classifiers for
specific categories of mutation.Supplemental Data
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